SC
NBIX icon

SouthState Corp’s Neurocrine Biosciences NBIX Stock Holding History

SouthState Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.85K Hold
11
– – ﹤0.01% 966
2026
Q1 		$1.45K Hold
11
– – ﹤0.01% 974
2025
Q4 		$1.56K Hold
11
– – ﹤0.01% 1038
2025
Q3 		$1.54K Hold
11
– – ﹤0.01% 982
2025
Q2 		$1.38K Sell
11
-24
-69% -$2.75K ﹤0.01% 1187
2025
Q1 		$3.87K Buy
+35
New +$4.43K ﹤0.01% 1039

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SouthState Corp's NBIX Position: Q2 2026 in Review

SouthState Corp held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 11 shares worth $1.85K. The position accounts for ﹤0.01% of the portfolio, ranked #966.

SouthState Corp first reported a position in NBIX in Q1 2025 and has held it in 6 quarters since. The position peaked at $3.87K in Q1 2025. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • SouthState Corp held 11 shares of Neurocrine Biosciences worth $1.85K as of Q2 2026.
  • SouthState Corp left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of SouthState Corp's portfolio in Q2 2026, its #966 holding.
  • SouthState Corp first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 6 quarters since.
  • SouthState Corp's Neurocrine Biosciences position peaked at $3.87K in Q1 2025.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on SouthState Corp's 13F filing for Q2 2026, filed 6 Aug 2026.